Want to see CLRB full AI Analyst Report?
CLRB Stock Chart & Stats
$3.29
-$0.03(-9.33%)
At close: 4:00 PM EST
$3.29
-$0.03(-9.33%)
Day’s Range― - ―
52-Week Range$2.20 - $6.52
Previous CloseN/A
Volume1.30M
Average Volume (3M)105.19K
Market Cap
$22.46M
Enterprise Value$1.10M
Total Cash (Recent Filing)$8.35M
Total Debt (Recent Filing)$1.53M
Price to Earnings (P/E)―
Beta1.27
Next Earnings
Aug 19, 2026EPS Estimate
-0.48Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-7.38
Shares Outstanding7,991,812
10 Day Avg. Volume157,484
30 Day Avg. Volume105,193
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.78
Price to Sales (P/S)0.00
P/FCF Ratio-0.33
Enterprise Value/Market Cap0.05
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit9.98
Enterprise Value/Ebitda-0.05
Forecast
1Y Price Target
$10.33Price Target Upside214.08% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-2.13
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Robust Phase IIb Clinical Efficacy (CLOVER WaM)Sustained, high response rates and long duration of response at 12 months indicate a clinically differentiated profile versus existing options in relapsed/refractory Waldenström macroglobulinemia. Durable efficacy drives a stronger regulatory case, physician adoption potential, and lasting commercial differentiation if confirmed in Phase III.
Clear Regulatory Pathway With Breakthrough DesignationBreakthrough designation and a defined confirmatory Phase III strategy materially shorten regulatory uncertainty compared with typical oncology developers. A concrete PFS‑based trial design and timeline create a durable path to approval that, if met, reduces time-to-market and makes future commercialization and partner discussions more tractable.
Material Financing Structured To Support Pivotal DevelopmentAccess to substantial upfront proceeds and contingent milestone funding materially extends runway for pivotal work and commercialization planning. This structural capital support reduces immediate insolvency risk, enabling execution of the Phase III plan and program continuity while the company pursues regulatory milestones and partnering options.
Bears Say
Sustained Cash Burn And Pre-revenue ModelPersistent negative operating and free cash flow reflects a business model still fully dependent on development funding rather than product sales. Over a multi‑quarter horizon this structural burn requires continued financing or partnerships; failure to secure those resources would force program delays or severe cutbacks.
Eroded Equity Cushion And Balance Sheet FragilityA materially reduced equity base limits the company's ability to absorb setbacks or pursue parallel development paths. Lower shareholder equity reduces leverage capacity and increases likelihood of dilutive financing, making balance sheet resilience fragile during the multi‑quarter pivotal development and commercialization phases.
Milestone‑contingent Financing With Market ConditionsA large portion of committed capital depends on achieving clinical/regulatory milestones and meeting market trading thresholds, linking funding directly to execution and market performance. If milestones slip or market conditions are unfavorable, the company risks funding shortfalls that could delay trials or require more dilutive raises.
Cellectar Biosciences News
CLRB FAQ
What was Cellectar Biosciences’s price range in the past 12 months?
Cellectar Biosciences lowest stock price was $2.20 and its highest was $6.52 in the past 12 months.
What is Cellectar Biosciences’s market cap?
Cellectar Biosciences’s market cap is $22.46M.
When is Cellectar Biosciences’s upcoming earnings report date?
Cellectar Biosciences’s upcoming earnings report date is Aug 19, 2026 which is in 46 days.
How were Cellectar Biosciences’s earnings last quarter?
Cellectar Biosciences released its earnings results on May 14, 2026. The company reported -$1.33 earnings per share for the quarter, beating the consensus estimate of -$1.885 by $0.555.
Is Cellectar Biosciences overvalued?
According to Wall Street analysts Cellectar Biosciences’s price is currently Undervalued.
Does Cellectar Biosciences pay dividends?
Cellectar Biosciences does not currently pay dividends.
What is Cellectar Biosciences’s EPS estimate?
Cellectar Biosciences’s EPS estimate is -0.48.
How many shares outstanding does Cellectar Biosciences have?
Cellectar Biosciences has 7,991,812 shares outstanding.
What happened to Cellectar Biosciences’s price movement after its last earnings report?
Cellectar Biosciences reported an EPS of -$1.33 in its last earnings report, beating expectations of -$1.885. Following the earnings report the stock price went up 8.844%.
Which hedge fund is a major shareholder of Cellectar Biosciences?
Currently, no hedge funds are holding shares in CLRB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cellectar Biosciences
Cellectar Biosciences is a biopharmaceutical firm engaged in the research, development, and market introduction of therapeutic agents to combat cancer. The company's primary asset is CLR 131 (iopofosine I-131), a phospholipid drug conjugate (PDC), which is currently undergoing several clinical evaluations. It is in Phase 2 clinical trials for individuals with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies. Additionally, CLR 131 is being studied in Phase 2B for r/r multiple myeloma (MM) and in Phase I trials targeting a range of pediatric cancers, r/r head and neck cancers, and R/R MM. Furthermore, Cellectar is advancing CLR 1900, another PDC-based chemotherapeutic program, which is in preclinical stages with the aim of treating solid tumors. The firm also participates in collaborative PDC development initiatives with partners such as Avicenna Oncology GMBH for the CLR 2000 Series, Orano Med for the CLR 12120 Series, as well as IntoCell Inc. and LegoChemBio. Established in 2002, Cellectar Biosciences maintains its corporate headquarters in Florham Park, New Jersey.
CLRB Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized major clinical progress for iopofosine (robust Phase IIb 12‑month data with high ORR, durable responses, and regulatory strategy toward accelerated approval) and an oversubscribed financing structure intended to fund late‑stage development. Operational progress on CLR125 and cost discipline were also highlighted. Key risks include a low pre‑financing cash balance, reliance on milestone‑contingent funding with market‑performance conditions, continued net losses, and tight timelines for Phase III initiation and regulatory milestones. On balance, the positive clinical data and financing momentum significantly outweigh the contingent funding and timing risks.View all CLRB earnings summariesCLRB Stock 12 Month Forecast
Average Price Target
$10.33
▲(214.08% Upside)
Technical Analysis
Ownership Overview
0.59% Insiders
1.38% Mutual Funds
1.56% Other Institutional Investors
95.45% Public Companies and
Individual Investors